Showing results (441-450 of 511) with videos related to

Sort By:
Pageof 52
Frontiers in Oncology|April 10, 2023
Real-world risk of brain metastases in stage III non-small cell lung cancer in the era of PET and MRI stagingSaud Alhusaini, Tyler A Lanman, Ryan B Ko, et al.
Research Square|June 29, 2026
Challenges in AI Based Tumor Board Case Summarization and RecommendationsWen-Wai Yim, Hendrik Damm, Tabea M G Pakull, et al.
Diabetes|June 19, 2015
Insulin Delivery Into the Peripheral Circulation: A Key Contributor to Hypoglycemia in Type 1 DiabetesJustin M Gregory, Guillaume Kraft, Melanie F Scott, et al.
Circulation|June 28, 2022
Identification of Pathogenic Immune Cell Subsets Associated With Checkpoint Inhibitor-Induced MyocarditisHan Zhu, Francisco X Galdos, Daniel Lee, et al.
Clinical Chemistry|January 4, 2021
Giant Magnetoresistive Nanosensor Analysis of Circulating Tumor DNA Epidermal Growth Factor Receptor Mutations for Diagnosis and Therapy Response MonitoringJared C Nesvet, Katie A Antilla, Danielle S Pancirer, et al.
Cancer Discovery|October 1, 2013
A drug repositioning approach identifies tricyclic antidepressants as inhibitors of small cell lung cancer and other neuroendocrine tumorsNadine S Jahchan, Joel T Dudley, Pawel K Mazur, et al.
JTO Clinical and Research Reports|December 3, 2024
Phase II Trial of Regorafenib and Oral Methotrexate in Previously Treated Advanced KRAS-Mutant NSCLCJacqueline V Aredo, Heather A Wakelee, Kavitha J Ramchandran, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 3, 2022
Phase II Randomized Study of Ramucirumab and Pembrolizumab Versus Standard of Care in Advanced Non-Small-Cell Lung Cancer Previously Treated With Immunotherapy-Lung-MAP S1800AKaren L Reckamp, Mary W Redman, Konstantin H Dragnev, et al.
JTO Clinical and Research Reports|March 7, 2023
Osimertinib in NSCLC With Atypical EGFR-Activating Mutations: A Retrospective Multicenter StudyJingran Ji, Jacqueline V Aredo, Andrew Piper-Vallillo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 17, 2018
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung CancerNathan A Pennell, Joel W Neal, Jamie E Chaft, et al.
Pageof 52